HKSE •
Healthcare •
Drug Manufacturers - Specialty & Generic •
Quote as of 07/29/2026 15:55
Company Profile
IndustryDrug Manufacturers - Specialty & Generic
SectorHealthcare
ExchangeHKSE
Market Capitalization15,716 mln
Float514 mln
Earnings Date07/30/2026
EPS
4.16
Solid
P / E
4.32
Deeply undervalued
Piotroski F-Score
4
/ 9
Borderline
Beneish M-Score
-1.24
Manipulation likely
1-Year Forecast
33.14
Transformational upside
Relative Strength
47
/ 100
In line with market
Business Description
HUTCHMED (China) Limited is a Hong Kong-based biopharmaceutical company founded in 2000 that researches and brings to market treatments for cancer and immune system disorders across global markets. The company has built a broad portfolio of drug candidates targeting a wide range of conditions, including colorectal cancer, lung cancer, leukemia, and autoimmune blood disorders, with several products already approved and others advancing through clinical trials. HUTCHMED works alongside major pharmaceutical partners such as AstraZeneca, Lilly, and Takeda to accelerate the development and distribution of its medicines.
